Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-I7 Post-CAR T-cell Therapy in Relapsed/Refractory Large B-cell Lymphoma
NCT07052305Phase 1Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Mar 2026
- Primary completion
- Nov 2027
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of efineptakin alfa in diffuse large B-cell lymphoma (DLBCL) (3 arms), sponsored by Washington University School of Medicine. Primary endpoints: Incidence of Adverse Events at 90 days, Maximum Tolerated Dose at 35 days and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
efineptakin alfa
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07052305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07052305.